# argenx SE

Type: Company (ARGX)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/argenx-se
Canonical HTML page: https://getfinancebrief.com/entity/argenx-se

## Recent coverage (1 stories)

### Tenaya $0.66 vs $4; argenx $1,158 Target as $63B Biotech Trades
2026-09-09 08:13:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A Sunday morning research note lifted Wall Street Zen's view on two biotechs—argenx to buy and Tenaya from strong sell to sell—but the market implications diverge sharply. Finance readers get a comparison of a profitable $63 billion rare-disease leader trading at a 38.67 P/E against a $148.75 million speculative gene therapy name at -1.25 P/E.
Full story: https://getfinancebrief.com/story/tenaya-argenx-wall-street-zen-rating-divergence

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.